Separately, the FDA on Friday informally requested that Sarepta voluntarily pause shipments of another gene therapy, Elevidys, that is approved to treat a different type of muscular dystrophy and was ...

FDA places clinical hold on Sarepta's LGMD gene therapy trials after three deaths and revokes platform tech designation due ...

Staff from the the University of Minnesota’s Raptor Center will present free programs about birds of prey 10:30 a.m. and noon ...

The U.S. Food and Drug Administration ( FDA) has placed an immediate clinical hold on Sarepta Therapeutics' investigational ...

MANKATO — As Blue Earth County prepares to set its 2026 tax levy, preliminary numbers suggest good news for farmers and bad ...

The death of a third patient tied to a Sarepta Therapeutics gene therapy this year sent the company’s shares nosediving 36% ...

When men delay or avoid their healthcare needs it can impact women caregivers' health. Catherine Corriveau, with Movember, joins Jennifer Palma to discuss a study put out by UBC.

In a highly unusual move, Cambridge-based Sarepta said late Friday won’t comply with a request from the Food and Drug ...

Drugmaker Sarepta Therapeutics said late Friday it won’t comply with a request from the Food and Drug Administration to halt ...

Elevidys is a gene therapy approved to treat Duchenne muscular dystrophy. Last month, Sarapta halted sales of the therapy for non-ambulatory patients.

The Food and Drug Administration plans to ask Sarepta Therapeutics Inc. to pause shipments of its Elevidys treatment after ...

The Dow Jones Industrial Average slipped on Friday (July 18) amid reports that US President Donald Trump is pushing for ...